Neurocrine Biosciences Inc
NASDAQ:NBIX
Neurocrine Biosciences Inc
Cash from Financing Activities
Neurocrine Biosciences Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Cash from Financing Activities
$65.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
17%
|
CAGR 10-Years
29%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Neurocrine Biosciences Inc's Cash from Financing Activities?
Cash from Financing Activities
65.3m
USD
Based on the financial report for Dec 31, 2023, Neurocrine Biosciences Inc's Cash from Financing Activities amounts to 65.3m USD.
What is Neurocrine Biosciences Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
29%